Document is current
Any future updates will be listed below
-
Authors
Møller, Peter Loof
Rohde, Palle Duun
Dahl, Jonathan Nørtoft
Rasmussen, Laust Dupont
Nissen, Louise
Schmidt, Samuel Emil
McGilligan, Victoria
Gudbjartsson, Daniel F.
Stefansson, Kari
Holm, Hilma
Bentzon, Jacob Fog
Bøttcher, Morten
Winther, Simon
Nyegaard, Mette http://orcid.org/0000-0003-4973-8543
-
Funding
Funding for this research was provided by:
European Union Regional Development Fund (ERDF) EU Sustainable Competitiveness Programme for Northern Ireland
Northern Ireland Public Health Agency
Novo Nordisk Foundation Clinical Emerging Investigator grant (NNF21OC0066981)
Novo Nordisk Foundation Start Package grants for faculty recruitment (NNF0071050)
- License Information
-
More Information
Article History
Received: 29 August 2023
Accepted: 12 March 2024
First Online: 20 March 2024
Declarations
:
: The study follows the principles outlined in the Declaration of Helsinki. The study was approved by the Central Denmark Regional Committee on Health Research Ethics (record number: 1–10-72–190-14) and the Danish Data Protection Agency (record number: 1–16-02–345-14). Informed written consent was obtained from all patients prior to enrollment. The trial was registered at ExternalRef removed (unique identifier: NCT02264717).
: Not applicable.
: MB discloses advisory board participation for NOVO Nordisk, AstraZeneca, Pfizer, Boehringer Ingelheim, Bayer, Sanofi, Novartis, AMGEN, CLS-Behring, and Acarix. SES is a part‐time consultant in Acarix and minor shareholder of Acarix. DFG, KS, and HH are employees of deCODE genetics/Amgen Inc. The remaining authors have no competing interests.
